blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2783005

EP2783005 - RECOMBINANT SEROTYPE 5 (AC]5) ADENOVIRAL VECTORS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  25.08.2017
Database last updated on 25.09.2024
FormerExamination is in progress
Status updated on  25.02.2017
Most recent event   Tooltip25.08.2017Application deemed to be withdrawnpublished on 27.09.2017  [2017/39]
Applicant(s)For all designated states
Targovax Oy
Saukonpaadenranta 2
00180 Helsinki / FI
[2016/30]
Former [2014/40]For all designated states
Oncos Therapeutics Ltd.
Saukonpaadenranta 2
00180 Helsinki / FI
Inventor(s)01 / RANKI, Tuuli
Urpukuja 1
FI-11130 Riihimäki / FI
02 / HEMMINKI, Akseli
Pohjoinen Hesperiankatu 37 A 22
FI-00260 Helsinki / FI
03 / CERULLO, Vincenzo
Uimarinpolku 10 C 15
FI-00330 Helsinki / FI
04 / KOSKI, Anniina
Leppävaarankatu 19 B 29
FI-02600 Espoo / FI
 [2014/40]
Representative(s)Boco IP Oy Ab
Kansakoulukatu 3
00100 Helsinki / FI
[N/P]
Former [2014/40]Boco IP Oy Ab
Itämerenkatu 5
00180 Helsinki / FI
Application number, filing date12852023.623.11.2012
WO2012FI51162
Priority number, dateFI2011000618125.11.2011         Original published format: FI 20116181
US201161563634P25.11.2011         Original published format: US 201161563634 P
[2014/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013076374
Date:30.05.2013
Language:EN
[2013/22]
Type: A1 Application with search report 
No.:EP2783005
Date:01.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 30.05.2013 takes the place of the publication of the European patent application.
[2014/40]
Search report(s)International search report - published on:FI30.05.2013
(Supplementary) European search report - dispatched on:EP22.06.2015
ClassificationIPC:C12N15/861, A61K35/76, A61K48/00, C12N5/10, A61P35/00, A61K35/761, C12N15/86
[2015/30]
CPC:
A61K35/761 (EP,FI,US); C12N15/8616 (FI); C12N7/00 (US);
A61K39/235 (US); A61K45/06 (US); A61K48/005 (FI);
A61P35/00 (EP); C12N15/86 (EP,US); C12N5/10 (FI);
C12N2710/10021 (US); C12N2710/10032 (US); C12N2710/10034 (US);
C12N2710/10052 (US); C12N2710/10332 (EP,US); C12N2810/6018 (EP,US) (-)
Former IPC [2014/40]C12N15/861, A61K35/76, A61K48/00, C12N5/10, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/40]
TitleGerman:REKOMBINANTE SEROTYP-5-(AC]5)-ADENOVIRUSVEKTOREN[2014/40]
English:RECOMBINANT SEROTYPE 5 (AC]5) ADENOVIRAL VECTORS[2014/40]
French:NOUVEAUX VECTEURS THÉRAPEUTIQUES[2014/40]
Entry into regional phase25.06.2014National basic fee paid 
25.06.2014Search fee paid 
25.06.2014Designation fee(s) paid 
25.06.2014Examination fee paid 
Examination procedure25.06.2014Examination requested  [2014/40]
08.01.2016Amendment by applicant (claims and/or description)
24.02.2016Despatch of a communication from the examining division (Time limit: M04)
20.06.2016Reply to a communication from the examining division
15.02.2017Despatch of a communication from the examining division (Time limit: M02)
26.04.2017Application deemed to be withdrawn, date of legal effect  [2017/39]
19.05.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2017/39]
Divisional application(s)EP15186798.3  / EP3006566
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  24.02.2016
Fees paidRenewal fee
11.11.2014Renewal fee patent year 03
12.11.2015Renewal fee patent year 04
18.11.2016Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2003138405  (FUEYO JUAN [US], et al) [A] 1-22 * [0037], [0095], [0096], [0105]- [0107], [0109], [0112]- [115], [0238], Examples 9, 10, 12, 13, claims 1,2 ,7, 28-32, 40, 41, 48 and Figure 2 *;
 [IA]  - LEI N ET AL, "An oncolytic adenovirus expressing granulocyte macrophage colony-stimulating factor shows improved specificity and efficacy for treating human solid tumors", CANCER GENE THERAPY,, (20080801), vol. 16, no. 1, doi:10.1038/CGT.2008.46, pages 33 - 43, XP002571569 [I] 1 * the whole document * [A] 2-22

DOI:   http://dx.doi.org/10.1038/cgt.2008.46
 [A]  - M. IACOBELLI-MARTINEZ ET AL, "Preferential Activation of Toll-Like Receptor Nine by CD46-Utilizing Adenoviruses", JOURNAL OF VIROLOGY, (20061115), vol. 81, no. 3, doi:10.1128/JVI.01926-06, ISSN 0022-538X, pages 1305 - 1312, XP055194212 [A] 1-22 * Page 1310 of the Discussion. *

DOI:   http://dx.doi.org/10.1128/JVI.01926-06
 [A]  - HAN HSI WONG ET AL, "Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles", VIRUSES, (20100111), vol. 2, no. 1, doi:10.3390/v2010078, pages 78 - 106, XP055149118 [A] 1-22 * Results (pages 35-36) and Figure 1. *

DOI:   http://dx.doi.org/10.3390/v2010078
International search[A]WO2010072900  (ONCOS THERAPEUTICS [FI], et al);
 [A]EP1990418  (DNATRIX INC [US]);
 [A]WO2009127666  (GLAXOSMITHKLINE BIOLOG SA [BE], et al);
 [A]US2011053893  (WU TOM YAO HSIANG [US], et al)
by applicantEP1377671
 US2003104625
 EP1767642
 WO2010072900
    - BERK, ANNU REV GENET, (1986), vol. 20, pages 45 - 79
    - FUEYO ET AL., ONCOGENE, (2000), vol. 19, pages 2 - 12
    - HEISE ET AL., NAT MED, (2000), vol. 6, pages 1134 - 9
    - HANAHAN; WEINBERG, CELL, (2000), vol. 100, pages 57 - 70
    - SCHULZ ET AL., NATURE, (2005), vol. 433, pages 887 - 92
    - MOEHLER ET AL., HUM GENE THER, (2005), vol. 16, pages 996 - 1005
    - PRESTWICH ET AL., EXPERT REV ANTICANCER, (2008), vol. 8, pages 1581 - 8
    - RUSSELL, J GEN VIROL, (2000), vol. 90, pages 1 - 20
    - NEMEROW ET AL., VIROLOGY, (2009), vol. 384, pages 380 - 8
    - RUSSELL W.C., J GENERAL VIROL, (2000), vol. 81, pages 2573 - 2604
    - MORAN, FASEB J, (1993), vol. 7, pages 880 - 5
    - RAWLE ET AL., J IMMUNOL, (1989), vol. 143, pages 2031 - 7
    - WOLD, J CELL BIOCHEM, (1993), vol. 53, pages 329 - 35
    - DANTHINNE; IMPERIALE, GENE THER, (2000), vol. 7, pages 1707 - 14
    - JOHNSON; SCHNEIDER-BROUSSARD, FRONT BIOSCI, (1998), vol. 3, pages 447 - 8
    - RULEY, NATURE, (1983), vol. 304, pages 602 - 6
    - RAYCHAUDHURI ET AL., GENES DEV, (1991), vol. 5, pages 1200 - 11
    - FATTAEY ET AL., MOL CELL BIOL, (1993), vol. 13, pages 7267 - 77
    - CERULLO ET AL., MOL THER, (2007), vol. 15, pages 378 - 85
    - TUVE ET AL., VACCINE, (2009), vol. 27, pages 4225 - 39
    - MATZINGER, ANNU REV IMMUNOL, (1994), vol. 12, pages 991 - 1045
    - LATZ ET AL., NAT IMMUNOL, (2007), vol. 8, pages 772 - 779
    - WANG ET AL., NATURE MEDICINE, (2011), vol. 17, pages 96 - 105
    - BIEDERMANN ET AL., J PATHOL, (2005), vol. 207, pages 199 - 206
    - ABBOD ET AL., EXPERT REV ANTICANCER THER, (2009), vol. 9, pages 867 - 870
    - TROJAN ET AL., ANTICANCER RES, (2005), vol. 25, pages 183 - 191
    - HARADA ET AL., ACTA DERM VENEREOL, (1996), vol. 76, pages 417 - 420
    - SCHMITT ET AL., J INVEST DERMATOL, (2007), vol. 127, pages 2191 - 2206
    - WICKHAM ET AL., CELL, (1993), vol. 73, pages 309 - 19
    - BOROVJAGIN ET AL., CANCER GENE THER, (2005), vol. 12, pages 475 - 86
    - KRASNYKH ET AL., J VIROL, (1998), vol. 70, pages 6839 - 46
    - SMITH ET AL., HUM GENE THER, (2003), vol. 14, pages 777 - 87
    - SMITH ET AL., HUMAN GENE THER, (2003), vol. 14, pages 1595 - 1604
    - KANERVA ET AL., GENE THER, (2005), vol. 12, pages 87 - 94
    - CERULLO ET AL., CANCER RES, (2010), vol. 70, pages 4297 - 309
    - KANERVA ET AL., MOL THER, (2003), vol. 3, pages 449 - 58
    - NETTELBECK ET AL., CANCER RES, (2002), vol. 62, pages 4663 - 70
    - KOSKI ET AL., MOL THER, (2010), vol. 18, pages 1874 - 84
    - TAKAYAMA ET AL., J. MED. VIROL, (2007), vol. 79, pages 278 - 284
    - JAGER, INT J CANCER, (1999), vol. 84, pages 506 - 510
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.